The global research landscape is currently undergoing a fundamental reorganization, shifting away from discretionary support toward rigid structural mandates. For decades, the international funding community—from major philanthropic foundations to corporate donors—has framed the inclusion of researchers from low- and middle-income countries (LMICs) as a goal to be encouraged. As of the May update for Global Health & WASH, that framework has been inverted. We are witnessing a decisive move where geographic leadership is no longer a soft aspiration, but a binary eligibility requirement for accessing capital.
The New Architecture of Research Equity
The most significant signal of this shift comes from Wellcome, which has anchored its latest funding cycle with three major calls that treat Global South leadership as a foundational design constraint. The ESIC Hubs initiative, offering between £1.5M and £1.9M per hub over a three-to-five-year period, explicitly mandates that the lead applicant be based in an LMIC. Similarly, the Infectious Disease Clinical Trial Development Award and the larger Infectious Disease Clinical Trial Award—which carries a funding range of £1M to £8M—require that the administering organization be rooted in eligible regions and that at least 50% of the applicant team be based there.
This is not an isolated trend. We see this pattern replicating across smaller-scale funders: CHINNOVA has channeled $1M into research institutions across West and Central Africa, while IBRO has tiered its Neuroscience Training Grants by region, ensuring the highest support—$5,000—is directed toward African researchers. Even Sidaction’s HIV Cure call now requires a minimum two-country collaboration involving eligible African nations. The implication is clear: research equity is being codified into the very legal and administrative architecture of global science.
Corporate Portfolios and the "Use-Inspired" Filter
While the non-profit sector focuses on leadership geography, pharmaceutical and corporate-linked funders are simultaneously professionalizing their research portfolios. The depth of the current lineup is striking, particularly with Pfizer and the Novo Nordisk Foundation running parallel, large-scale calls that emphasize "independent" and "use-inspired" research.
Pfizer’s current suite, which includes a $1M pool for Migraine IME and a $400K per-project call for Pediatric Pneumococcal Surveillance in Saudi Arabia, represents a deliberate effort to separate financial backing from commercial promotion. By funding quality improvement and evidence-based education, these entities are targeting measurable practice-relevant change. Meanwhile, the Novo Nordisk Foundation has deployed significant capital, including a DKK 60M pool for Infectious Diseases Catalyst Grants and DKK 53M for Non-Diabetic Endocrinology Collaborative Grants. These programs operate on a "hard filter" logic, pushing academic researchers to move beyond theoretical discovery toward a credible, deployable translation pathway.
AI: Moving from Speculation to Operational Hardship
Perhaps the most pragmatic shift identified this month is the treatment of artificial intelligence. Funders are no longer treating AI as a speculative trend; they are treating it as an operational component that requires strict governance. The Water Research Foundation has launched two AI calls, each worth $200K, that prioritize cybersecurity guardrails and human-in-the-loop deployments as non-negotiable design features.
The UNICEF Venture Fund, through its Climate Tech for Children’s Health call, has moved beyond funding prototypes, now requiring solutions to provide evidence of promising pilot results. TEF-Health is offering €300K in subsidized testing infrastructure to ensure that AI and robotics SMEs can meet the rigors of real-world healthcare environments. The collective takeaway is that the "pilot phase" of AI in public health is closing. The next reading of project milestone reports across these initiatives will show whether these technical innovations can actually be integrated into existing, resource-constrained policy timelines.
Limitations to Consider
While these shifts toward structural equity and operational rigor are welcome, they introduce significant barriers for smaller institutions. The move toward "hard eligibility" for LMIC-led research, while essential for long-term health sovereignty, may temporarily strain the administrative capacity of local organizations that now bear the burden of both scientific and financial leadership. Furthermore, the reliance on "use-inspired" corporate funding, while providing vital capital, necessitates constant vigilance regarding the independence of the generated evidence. Researchers must be prepared to navigate these heightened administrative requirements, as the next phase of global health funding will favor those who can master the intersection of high-level policy, operational feasibility, and local governance.
